ES2283860T3 - Agonistas deñ recptor nicotinico alfa-7 y estaninas combinados. - Google Patents

Agonistas deñ recptor nicotinico alfa-7 y estaninas combinados. Download PDF

Info

Publication number
ES2283860T3
ES2283860T3 ES03791540T ES03791540T ES2283860T3 ES 2283860 T3 ES2283860 T3 ES 2283860T3 ES 03791540 T ES03791540 T ES 03791540T ES 03791540 T ES03791540 T ES 03791540T ES 2283860 T3 ES2283860 T3 ES 2283860T3
Authority
ES
Spain
Prior art keywords
azabicyclo
oct
carboxamide
octan
thiophene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03791540T
Other languages
English (en)
Spanish (es)
Inventor
Richard Keith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2283860T3 publication Critical patent/ES2283860T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
ES03791540T 2002-09-02 2003-09-01 Agonistas deñ recptor nicotinico alfa-7 y estaninas combinados. Expired - Lifetime ES2283860T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202598 2002-09-02
SE0202598A SE0202598D0 (sv) 2002-09-02 2002-09-02 Alpha-7 Nicotinic receptor agonists and statins in combination

Publications (1)

Publication Number Publication Date
ES2283860T3 true ES2283860T3 (es) 2007-11-01

Family

ID=20288874

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03791540T Expired - Lifetime ES2283860T3 (es) 2002-09-02 2003-09-01 Agonistas deñ recptor nicotinico alfa-7 y estaninas combinados.

Country Status (12)

Country Link
US (2) US20050256146A1 (cg-RX-API-DMAC7.html)
EP (1) EP1545537B9 (cg-RX-API-DMAC7.html)
JP (1) JP2006505530A (cg-RX-API-DMAC7.html)
AT (1) ATE358485T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003256203A1 (cg-RX-API-DMAC7.html)
DE (1) DE60313004T2 (cg-RX-API-DMAC7.html)
DK (1) DK1545537T3 (cg-RX-API-DMAC7.html)
ES (1) ES2283860T3 (cg-RX-API-DMAC7.html)
PT (1) PT1545537E (cg-RX-API-DMAC7.html)
SE (1) SE0202598D0 (cg-RX-API-DMAC7.html)
SI (1) SI1545537T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004019947A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
CA2728675A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
FR2958850B1 (fr) * 2010-04-14 2012-07-06 Centre Nat Rech Scient Medicaments pour la prevention ou le traitement des addictions aux drogues
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 (R)-7-氯-N-(啶-3-基)苯並[b]噻吩-2-羧醯胺鹽酸鹽單水合物之結晶形體
EP2593447B1 (de) 2010-07-15 2016-08-17 Bayer Intellectual Property GmbH 3-pyridyl-heteroarylcarboxamidverbindungen als schädlingsbekämpfungsmittel
LT2685986T (lt) * 2011-03-18 2020-03-10 Genzyme Corporation Gliukozilceramido sintazės slopiklis
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
JPWO2013161871A1 (ja) * 2012-04-25 2015-12-24 興和株式会社 Tlr阻害作用を有するチオフェン誘導体
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
JP6401254B2 (ja) 2013-06-21 2018-10-10 武田薬品工業株式会社 プロキネシチン受容体のモジュレータとしての1−スルホニルピペリジン誘導体
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
CN103923105B (zh) * 2014-04-17 2016-08-24 北京大学 2-中氮茚甲酰胺类化合物及其制备和用途
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
EP3806956A4 (en) * 2018-06-13 2022-08-10 Zachriel Neurosciences, Llc METHODS AND DOSAGE REGIMES FOR PREVENTING OR DELAYING THE ONSET OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA AND MILD COGNITIVE IMPAIRMENT
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3708962B2 (ja) * 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
AR013184A1 (es) * 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
SE9903996D0 (sv) * 1999-11-03 1999-11-03 Astra Ab New compounds
WO2002017358A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
US20050222122A1 (en) * 2002-04-02 2005-10-06 Sean Lilienfeld Statin therapy for enhancing cognitive maintenance
AU2003279492A1 (en) * 2002-12-11 2004-06-30 Pharmacia & Upjohn Company Llc Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
WO2005092890A2 (en) * 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof

Also Published As

Publication number Publication date
HK1077193A1 (en) 2006-02-10
EP1545537A1 (en) 2005-06-29
SE0202598D0 (sv) 2002-09-02
WO2004019947A1 (en) 2004-03-11
US20090192180A1 (en) 2009-07-30
US20050256146A1 (en) 2005-11-17
DE60313004T2 (de) 2008-01-03
PT1545537E (pt) 2007-06-20
AU2003256203A1 (en) 2004-03-19
SI1545537T1 (sl) 2007-08-31
DK1545537T3 (da) 2007-07-02
DE60313004D1 (de) 2007-05-16
EP1545537B9 (en) 2008-08-20
EP1545537B1 (en) 2007-04-04
ATE358485T1 (de) 2007-04-15
JP2006505530A (ja) 2006-02-16

Similar Documents

Publication Publication Date Title
EP1545537B9 (en) Alpha-7 nicotinic receptor agonists and statins in combination
Oshaghi et al. Role of neurotransmitters in immune-mediated inflammatory disorders: a crosstalk between the nervous and immune systems
JP6199176B2 (ja) 頭部外傷誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果
Xu et al. Hippocampal mTOR signaling is required for the antidepressant effects of paroxetine
JP7146809B2 (ja) 医薬組成物の調製におけるシトクロムbc1複合体阻害剤の使用
EA019571B1 (ru) Применение сульфизоксазола для лечения болезни альцгеймера
Mans et al. Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice
JP2006505530A5 (cg-RX-API-DMAC7.html)
JP2002518448A (ja) 高血中コレステロールを治療する組成物および方法
Mahrooz Pharmacological interactions of paraoxonase 1 (PON1): a HDL-bound antiatherogenic enzyme
JP2006508189A (ja) 自己免疫障害の処置のためのコレステロール吸収インヒビター
TW202310842A (zh) 高強度他汀弱反應物之治療
US20060004076A1 (en) Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
Dang et al. TPPU inhibits inflammation-induced excessive autophagy to restore the osteogenic differentiation potential of stem cells and improves alveolar ridge preservation
EP3119406A1 (en) Methods for improving cognitive function via modulation of quinone reductase 2
JP2017095468A (ja) 虚血/卒中誘導性の記憶障害および脳障害におけるブリオスタチン、ブリオログ、および他の関連物質の治療効果
US12622895B2 (en) Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases
Emilien et al. Alzheimer disease: neuropsychology and pharmacology
JP2022521125A (ja) 脳内の炎症の抑制又は軽減剤
HK1077193B (en) Alpha-7 nicotinic receptor agonists and statins in combination
Tian et al. GALM Alleviates Aβ Pathology and Cognitive Deficit Through Increasing ADAM10 Maturation in a Mouse Model of Alzheimer’s Disease: N. Tian et al.: GALM improves AD
Strayhorn Jr Case Study: Cyproheptadine and Aggression in a Five‐Year-Old Boy
Ai et al. Research progress in the clinical treatment of familial hypercholesterolemia
PT1492539E (pt) Terapia de estatina para intensificar a manutenção cognitiva
JP2020193188A (ja) 慢性副鼻腔炎の予防剤または治療剤、およびこれらを製造するためのスタチンの使用